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Abstract
In the present review, we focus on evidence-based data for the use of inhaled corticosteroids (ICS), leukotriene
receptor antagonist (LTRA), long-acting beta2-agonits (LABA) and oral corticosteroids (OCS), with a special emphasis
on well-performed randomized clinical trials (RCTs) and meta-analyses of such trials for the chronic management of
asthma/wheeze in infants and preschoolers. Results: Seven meta-analyses and 14 RCTs were reviewed. Daily ICS
should be the preferred drug for infants/preschoolers with recurrent wheezing, especially in asthmatics. For those
with moderate or severe episodes of EVW, the use of high intermittent ICS doses significantly reduce the use of
OCS. There is no evidence of effect of intermittent ICS at low-moderate dose in preschoolers with mild EVW
episodes. In preschoolers with asthma, there were no significant differences between daily vs. intermittent ICS in
terms of asthma exacerbations with insufficient power to conclude to equivalence; however, for other asthma
control outcomes, daily ICS works significantly better than intermittent ICS for older children. Daily ICS is superior to
daily or intermittent LRTA for reducing symptoms, preventing exacerbations, and improving lung function. No RCTs
testing combination therapy with ICS and LABA (or LTRA) were published in infant/preschoolers. Parent-initiation of
OCS at the first sign of symptoms is not effective in children with recurrent wheezing episode. In terms of ICS
safety, growth suppression is dose and molecule-dependent but it’s effect is not cumulative beyond the first year of
therapy and may be associated with some catch-up growth while on or off therapy. Linear growth must be
monitored as individual susceptibility to ICS drugs may vary considerably.
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Background
Wheezing is a common symptom in the first years of life,
but a minority of children will continue to experience
wheezing symptoms in school years and beyond [1]. Based
on the epidemiologic data on the natural history and tem-
poral patterns of wheezing, several childhood wheezing
phenotypes have been described, with different risk factors
somewhat associated with each phenotype. However, the
use of these “epidemiologic” phenotypes such as transient
early, prolonged early, persistent (atopic and non-atopic),
late-onset, and intermediate-onset wheezing, is limited,
since they can only be identified retrospectively; indeed,
they were defined using statistical inference on longitudin-
ally collected data, and not useful in the present as they
are defined by events that will occur in the future [2].
Thus, it has been proposed that wheezing phenotypes be
based on the trigger(s) and temporality of symptoms (such
as episodic viral wheeze [EVW] and multiple-trigger
wheeze [MTW]) which can be ascertained in a clinic and
could be more practical to make treatment decisions [3].
However, classification of preschool wheezers into EVW
or MTW may change in up to 50 % of cases within a 1-
year period, suggesting that these phenotypes overlap con-
siderably, perhaps as children show and parents observed,
more symptoms with time or conversely show improve-
ment with therapy [4].
Effective management options for early-life asthma/
wheezing would be of great importance for a number of
reasons. First, the burden of disease is greatest in pre-
schoolers with a significantly higher proportion of emer-
gency department (ED) visits, more hospitalizations,
more sleep disturbances and more limitation of family
activities/play, than older children [5, 6]. Secondly, the
irreversible impairment in lung function may occur
during the preschool period, suggesting a window of op-
portunity to perhaps prevent irreversible damage; [7] It
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is possible that the repeated and cumulative lung injury
caused by various respiratory infections (e.g., rhinovirus,
respiratory syncytial virus, etc.) that are frequent at this
age maybe causal or important intercurrent factors af-
fecting lung growth and asthma persistence. Perhaps,
one of the reasons of that high morbidity among pre-
schoolers is that the diagnosis of asthma without lung
function testing is challenging, resulting in wide vari-
ation in treatment approaches, compounded by the pau-
city of evidence.
In the past 15 years, the diagnosis of asthma has hinged
on the ability to predict persistence of asthma at 6 years.
Several asthma predictive rules have emerged. The
Asthma Predictive Index (API) [8], originally developed in
the Tucson cohort study, is the most widely used. The
API is simple and cheap, and its major strength is its good
positive likelihood ratio ~7.4 (the post-test probability of
disease can improved from 2 to 7 times) and high specifi-
city (~97 %) [9].
In the present review, we will focus on chronic man-
agement of asthma/wheeze in preschoolers. We review
the evidence (RCTs and systematic reviews with meta-
analyses) for the use of inhaled corticosteroids (ICS),
leukotriene receptor antagonist (LTRA), oral corticoste-
roids (OCS), and long-active beta-2 agonists (LABA).
We present the most relevant data of the meta-analysis
performed for each specific topic and described the
RCTs not included in those meta-analyses. When no
meta-analysis was performed, RCTs were described. In this
review, we specifically did not consider the acute manage-
ment of asthma/wheeze at home, during emergency de-
partment (ED) visits or hospitalizations. We acknowledge
that these trials (RCTs) generally include heterogeneous
group of participants, with differences in age, inclusion cri-
teria, triggers, severity, and possibly diagnoses.
Results
Data extraction
We (JACR) performed a searched in PubMed and the
Cochrane Library with the keywords: (asthm* or wheez*)
AND (inhaled corticosteroids or corticosteroids or leu-
cotriene or leukotriene or montelukast or long-acting
beta agonists), limited for clinical trials or systematic re-
views and for infants or preschool children. We included
7 systematic reviews with meta-analysis of RCTs and 14
RCTs not included in the systematic reviews.
Inhaled corticosteroids
Daily ICS Wilson et al. [10] performed a parallel study
randomized 161 patients with EVW to ICS (budesonide
400 μg/day) or placebo administered over the course of
four months, and could not demonstrate any significant
of the active treatment on the use of rescue OCS, admis-
sion to hospital, overall symptom scores, number of
symptom-free days, severity of symptoms, or duration of
episodes between treatments when they compared vs.
placebo.
High quality evidence supports the use of ICS in infants
or pre-school children with recurrent wheezing or asthma
for at least 6 months before study entry. Castro-
Rodriguez and Rodrigo [11] conducted a meta-analysis on
29 RCTs (n = 3592) to compare the efficacy of ICS vs. pla-
cebo in infants and preschoolers with recurrent wheezing
or asthma. They reported that patients who received ICS
had significantly less wheezing/asthma exacerbations re-
quiring OCS than those on a placebo (RR = 0.59, 95 % CI
[0.52–0.67], p = 0.0001, I2 = 10 %), and with a NNT = 7
[6–9], (Fig. 1). Post-hoc subgroup analysis suggests that al-
though ICS is effective in asthma and recurrent wheez-
ing, but with stronger effect in those with a diagnosis
of asthma than wheezing (interactive test RR = 0.76
[0.58–0.99], p = 0.04); but was independent of age (infants
vs. preschoolers), atopic condition, type of inhaled cortico-
steroid (budesonide vs. fluticasone), mode of delivery
(metered-dose inhaler [MDI] vs. nebulizer), and study
quality and duration (<12 vs. ≥ 12 weeks). In addition, chil-
dren treated with ICS had significantly fewer withdrawals
caused by wheezing/asthma exacerbations, less albuterol
use, and more clinical and functional improvement than
those on placebo.
In conclusion daily treatment with ICS is consistently
appears as an effective strategy in preschoolers with re-
current wheezing, especially those with asthma diagnosis,
including those with EVW.
Intermittent ICS A Cochrane review conducted by
McKean & Ducharme [12] with 3 RCT (n = 122 pre-
schoolers with EVW), 2 cross-over and 1 parallel study
comparing high ICS doses (1.6–2.25 mg per day) show a
reduction in requirement for OCS among those with
ICS vs. placebo (RR = 0.53 [0.27–1.04] for the 2 cross-
over studies, and RR = 0.82 [0.52–1.29] for the parallel
study), (Fig. 2). In terms of ED/doctor visits, only one
study reported this outcome and shows an effect favor-
ing ICS (RR = −0.70 [0.50 to 0.97]); in terms of hospital
admissions, the effect of ICS was not significant different
compared with placebo. However, a recently published
parallel RCT [13] comparing intermittent beclometha-
sone by nebulizer (400 μg twice daily) vs. placebo for
10 days in 525 Italian preschoolers with mild EVW (had
at least 1 episode of viral wheezing diagnosed by a phys-
ician in the preceding 12 months, and had no or min-
imal asthma-like symptoms between distinct airway
infections) showed no group difference in % of wheezing
diagnosed by the pediatrician during a upper respiratory
tract infection episode (primary outcome) nor reducing
severity of wheezing, asthma-like symptoms score, extra
visits, ED attendance, prescription of rescue drugs.
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Fig. 2 Pooled RRs (with 95 % CI) for exacerbation requiring oral steroids of eligible studies comparing episodic ICS vs placebo in infants or
preschoolers [12]. (reproducing with the author’s permission)
Fig. 1 Pooled RRs (with 95 % CI) for wheezing/asthma exacerbations of eligible studies comparing ICSs vs. placebo in infants or preschoolers [11].
(reproducing with the author’s permission)
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Recently, Ducharme et al. [14] performed a meta-
analysis of 4 new RCTs (n = 1024) reporting a reduced
risk of exacerbations need rescue OCS in preschoolers
with moderate or severe EVW using high ICS doses
vs. placebo (RR = 0.68 [0.53–0.86], but the difference did
not reach significance in asthma-free days (MD= 2.01
[−2.23–6.25], (Fig. 3a and b).
In conclusion, for infants and preschoolers with EVW
and recurrent wheezing, the use of high intermittent ICS
doses significantly reduce the use of OCS in those
with moderate or severe episodes; no apparent effect of
intermittent low-moderate doses of ICS in children with
mild EVW episodes.
Daily vs. intermittent ICS A meta-analysis conducted
by Rodrigo & Castro-Rodriguez [15] evaluated daily vs.
intermittent ICS among preschoolers (2 RCTs, n = 498),
school-age children (2 RCTs, n = 259) and adults (3
RCTs) with persistent wheezing and mild to moderate
stable persistent asthma. There was no statistically sig-
nificant difference in the rate of asthma exacerbations
between the two strategies in all patients (RR = 0.96
Fig. 3 a Pooled RR (with 95 % CI) for exacerbations needing rescue oral steroids of eligible studies comparing pre-emptive ICS vs. placebo in infants
or preschoolers [14]. (reproducing with the author’s permission). b Mean group difference (with 95 % CI) of percentage of asthma-free days of
eligible studies comparing pre-emptive ICS vs. placebo in infants or preschoolers [14]. (reproducing with the author’s permission)
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[0.86–1.06], p = 0.40, I2 = 0 %). Sub-group analysis did not
identify significant group differences regarding age, dur-
ation of studies, or step-up strategy. However, the daily
ICS group (in all patients) had a significant greater in-
crease in asthma-free days (RR = 1.10 %, 95 % CI: [1.01 to
1.20], p = 0.03, I2 = 10 %, NNT = 22, 95 % CI [9 to58]) than
those treated with intermittent high-dose ICS. There were
no significant differences in rescue medication use, ex-
haled nitric oxide measurement, and children’s linear
growth rate between daily and intermittent ICS.
Later, a Cochrane meta-analysis by Chauhan et al. [16]
compared the efficacy and safety of intermittent vs. daily
ICS for the management of children and adults with per-
sistent asthma published October 2012. The review in-
cluded 2 RCTs involving 498 preschoolers (the same
studies included by the former meta-analysis) and 3 in-
volving school-age children (5–18 years) and 2 adult trials.
When analyzing patients of all ages, the daily ICS group
was associated with a statistically significant improvement
in the change from baseline PEFR, more symptom-free
days, more asthma control days, less use of rescue medica-
tion, and a greater reduction in the change from baseline
in exhaled nitric oxide vs. intermittent ICS group. In the
subgroup analysis focusing on preschoolers, there were no
significant difference in exacerbations requiring OCS
among intermittent vs. daily ICS (RR = 1.26 [0.84–1.88], p
= 0.49, I2 = 43 %), but there is insufficient evidence to con-
clude to equivalence. (Fig. 4). Among preschool and
school-aged children, intermittent ICS were associated
with greater growth by 0.41 cm change from baseline (p =
0.004) compared to daily treatment.
In conclusion, there were no significant differences be-
tween daily vs. intermittent ICS in terms of asthma exacer-
bations but insufficient data to conclude to equivalence.
however, for other asthma control outcomes, daily ICS
works significantly better than intermittent ICS for older
children.
Safety of ICS Of the adverse effects associated with
ICS, growth suppression is the most concerning for phys-
ician and parents. Most RCT focused on pre-pubertal
school-aged children. Only few RCTs on preschoolers re-
ported this adverse effect. Specifically, in a RCT on daily
low dose (fluticasone 100 μg twice daily) vs. sodium
cromoglycate for 52 weeks, there was no significant differ-
ence in mean adjusted growth rates between the two
groups: 84.0 mm/year vs. 86.4 mm/year, respectively (dif-
ference: −2.4 mm/year, 95 % CI −6.6 to 1.8) [17]. In a RCT
on intermittent high-dose (fluticasone 750 μg twice daily
for 10 days), the difference in height between ICS and pla-
cebo was also small −0.61 cm [−1.31 to 0.09] [18].
In predominantly school-aged children with mild to mod-
erate persistent asthma, a recent systematic review by Zhang
et al. [19] showed that regular use of ICS at low or medium
daily doses was associated with a statistically significant
growth suppression measured by linear growth velocity,
change from baseline in height, and change in height SDS
during a one-year treatment period. Compared with placebo
or non-steroidal drugs, ICS was associated with a statisti-
cally significant reduction in linear growth velocity (N = 14
RCTs, n = 5717 participants, MD −0.48 cm/yr [−0.65 to
−0.30], moderate quality evidence) and in the change from
baseline in height (N = 15 RCTs, n = 3275 participants, MD
−0.61 cm/y [−0.83 to–0.38], moderate quality evidence) dur-
ing a one-year treatment period. In the subgroup of toddlers
or infants (N = 2, n = 903), the change in the baseline of
height (cm) during one year of treatment was of similar
magnitude than that of placebo: MD −0.58 [−0.55 to −0.20],
p = .003, I2 = 16 %, (Fig. 5). The subgroup analysis on 14
RCTs indicated that the effect size of ICS on linear
growth velocity appeared to be associated more
strongly with the ICS molecule (with apparent greater
suppression of beclomethasone, budesonide and prob-
ably mometasone compared to ciclosenide, flutica-
sone) than with the device or dose. ICS-induced
growth suppression seemed to be maximal during the
first year of therapy and less pronounced during sub-
sequent years of treatment. Although catchup growth
up to 12 months after ICS cessation has been docu-
mented, limited evidence suggests that ICS-induced
growth suppression in pre-pubertal school-aged chil-
dren with prolonged daily ICS therapy may persist
until they reach adult height. Indeed, a trial with
follow-up into adulthood showed that participants of
pre-pubertal age treated with budesonide 400 μg/day
for a mean duration of 4.3 years had a mean reduc-
tion of 1.20 cm [−1.90 to −0.50] in adult height com-
pared with those treated with placebo [20].
In conclusion, ICS may be associated with growth sup-
pression although the evidence is limited in preschoolers.
In pre-pubertal school-aged children, the growth suppres-
sion appears neither progressive nor regressive, and it is
not cumulative beyond the first year of therapy. Conse-
quently, it is prudent to monitor linear growth in all chil-
dren treated with ICS, irrespective of age, given that
individual susceptibility to these drugs may vary consider-
ably and select molecules with the less growth suppression
and lower the dose to the minimal effective one.
LTRA (daily and intermittent)
A recent Cochrane review [21] of RCTs with a parallel-
group or cross-over (for intermittent LTRA only) design
evaluated the evidence for the efficacy and safety of
maintenance (more than 2 months) and intermittent
(<14 days) LTRAs in the management of EVW in pre-
schoolers. Five RCTs (one investigated maintenance
treatment, three intermittent therapy and one had both
maintenance and intermittent treatment arms) included
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3741 participants. Each study involved oral montelukast
and was of good methodological quality. For mainten-
ance treatment, specific data obtained from a single
study (n = 341), limiting to children with only an EVW
phenotype, showed no statistically significant group re-
duction in the number of episodes requiring rescue oral
corticosteroids associated with daily montelukast versus
placebo (OR = 1.20 [0.70 to 2.06], moderate quality evi-
dence). For intermittent LTRA, pooled data (n = 343)
showed no statistically significant reduction in the
number of episodes requiring rescue OCS in children
treated with LTRA versus placebo (OR = 0.85 [0.64 to
1.14], p = 0.29, I2 = 0), (Fig. 6). Specific data for children
with an EVW phenotype obtained from a single study
(n = 963) of intermittent montelukast treatment showed
a small, but statistically significant reduction in unsched-
uled medical attendances due to wheeze (RR = 0.83 [0.71
to 0.98]). For maintenance compared to intermittent
LTRA treatment, no data relating to the primary out-
come (one or more viral-induced episodes requiring
Fig. 4 Pooled RR (with 95 % CI) for exacerbation requiring oral corticosteroids of eligible studies comparing intermittent ICS vs. daily ICS in
infants or preschoolers [16]. (reproducing with the author’s permission)
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treatment with OCS) of the review were identified.
There were no other significant group differences identi-
fied in other secondary efficacy outcomes for mainten-
ance or intermittent LTRA treatment versus placebo, or
maintenance versus intermittent LTRA treatment. No
differences on adverse events were found.
Knorr et al. [22] randomly assigned 689 children (aged
2–5 years) with a history of physician-diagnosed asthma
to 12 weeks of treatment with montelukast or a placebo.
Montelukast produced significant improvements com-
pared with a placebo in daytime and overnight asthma
symptoms, the percentage of days without asthma, the
need for rescue bronchodilator or OCS use, physician
global evaluations, and peripheral blood eosinophils.
Recently, a multicentre parallel-group randomized
placebo-control trial [23], was carried out in 1358 children
(aged 10 months to 5 years) with two or more wheeze epi-
sodes who were stratified by genotype into either a 5/5 or
5/x or x/x ALOX5 (arachidonate 5-lipoxygenasae) pro-
moter genotype stratum, then randomly assigned to re-
ceive intermittent montelukast or placebo given by the
parents at each wheeze episode over a 12 month period.
There was no difference in unscheduled medical atten-
dances for wheezing episodes (primary outcome) between
children in the montelukast and placebo groups. Compared
with placebo, unscheduled medical attendance for wheezing
episodes were reduced in children given montelukast in the
5/5 stratum (IRR 0.80, 95 % CI 0.68–0.95, p = 0.01), but not
in the 5/x + x/x stratum. The data suggest no clear benefit
of intermittent montelukast in groups of young chil-
dren with wheeze; however, the 5/5 ALOX5 pro-
moter genotype might identify a montelukast-responsive
subgroup.
In conclusion in preschoolers with EVW, there is no
evidence of benefit associated with maintenance or
intermittent LTRA treatment, compared to placebo, for
reducing the number of children with one or more epi-
sodes requiring rescue oral corticosteroids, and little evi-
dence of significant clinical benefit for other secondary
outcomes. Therefore until further data are available,
LTRA should be used with caution in individual chil-
dren. It is likely that children with an apparent EVW
phenotype are not a homogeneous group and that sub-
groups may respond to LTRA treatment depending on
given genotype and the exact patho-physiological mech-
anism involved.
ICS vs. LTRA
At present, only few RCTs comparing daily ICS vs.
LTRA in infants/preschoolers were performed. Kooi et
al. [24] completed a small RCT (n = 63 Dutch children
aged 2–6 years. with asthma-like symptoms) comparing
daily fluticasone (100 μg twice daily) vs. montelukast
(4 mg/day) vs. placebo for three months. Despite lack of
power, the results suggest that fluticasone has a signifi-
cant greater beneficial effect on symptoms than placebo,
while montelukast significant decreased the blood eo-
sinophil level compared to placebo. Children on
Fig. 5 Mean difference (with 95 % CI) of change from baseline in height (cm) during one year of treatment comparing no steroids drugs vs. ICS [19].
(reproducing with the author’s permission)
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fluticasone had significant better lung function parame-
ters (lower airway resistance) than those on
montelukast.
Krawiec et al. [25] carried out a small study in Poland
in which 70 children aged 6 to 36 months with one to
three wheezing episodes were randomized to receive ei-
ther montelukast (4 mg), fluticasone (50 or 100 μg /day,
<12 or ≥ than 12 months of age respectively) or no treat-
ment for 12 weeks. There were no significant differences
in primary outcome (number and percentage of wheez-
ing episode within one year) between groups.
A RCT [26] on 2400 Pakistani children age 6 months
to 5 years (mean age of 2.4 ± 1.25 years) with uncon-
trolled asthma randomized participants to ICS (200 μg
/day) or montelukast (4 mg in children under one year
of age, and 5 mg in those older) for 6 months. Failure of
treatment was consider if patients were admitted to ED
due to wheezing exacerbation. After 6 months of treat-
ment, 51.6 % of children on ICS vs. 16.7 % on montelu-
kast stepped-down therapy. On the other hand, 6.4 % of
children on ICS vs. 32.1 % on montelukast were
stepped-up therapy. Only one patient on ICS and two
on montelukast were admitted to ED. However, no more
details were found in the publication, limiting the
interpretation.
Li YQ et al. [27] completed the first RCT comparing
children with positive and negative API. In this trial, 239
wheezing Chinese children aged 17 to 60 months of age
were divided into API-positive (n = 126) and API-
negative groups (n = 113). Each group was randomly
assigned to budesonide suspension or montelukast for
four weeks. Asthma symptom scores were assessed and
recorded at different time points. In the first four weeks
of treatment, budesonide and montelukast were effective
on symptoms among children with API positive and API
negative. After 24 weeks of treatment, montelukast
works better on symptoms than budesonide among chil-
dren with API positive; however, both drugs works
equally among children with API negative.
In conclusion, only few RCTs were performed compar-
ing daily ICS vs. montelukast in infant/preschoolers,
with no clear superiority between those drugs. However,
at this moment, no RCT was published in a cross-over
comparison of ICS vs LTRA in infants/preschoolers with
recurrent wheezing and positive or negative API.
Intermittent OCS at home
Since children with EVW have episodic exacerbations
triggered by viral respiratory infections, another thera-
peutic strategy for treating children with EVW consists
of keeping the OCS at home, and having parents com-
mence their use at the first sign of symptoms, without
waiting for a medical review, in an effort to abort the at-
tack. Short courses (3–5 days) of OCS (generally pred-
nisolone) are commonly administered in this way.
In a crossover RCT study [28] 86 children (aged 2–
4 years.) from a primary-care clinic and ED of an
inner-city teaching hospital who had made two or
more outpatient (ED or primary-care clinic) visits for
acute asthma in the preceding year were enrolled for
12 months (6 months prednisone [2 mg/k up to
60 mg) or 6 months placebo). Parents were instructed
to give their child one capsule for an asthma attack
that had not improved after a dose of the child’s
Fig. 6 Pooled RR (with 95 % CI) for number of participants experiencing one or more episode requiring treatment with oral corticosteroids of
eligible studies comparing intermittent LRTA vs. placebo in infants or preschoolers [21]. (reproducing with the author’s permission)
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regular acute asthma medicine. Neither the total num-
ber of attacks nor the number for which medicine was
used differed significantly by arm of study. There was
a larger number of attacks resulting in outpatient visits
when children were in the group that received pred-
nisone (1.1 ± 0.59 versus 0.59 ± 0.86). This trend was
less pronounced but persisted when limited to attacks
for which the medicine was given (0.58 ± 0.99 versus
0.35 ± 0.55). Neither the number of attacks resulting in
admission nor the number of hospital days differed
significantly by arm of study. Oommen et al. [29] stud-
ied 217 children aged 1 to 5 years admitted to hospital
with EVW who were randomized for parent-initiated
prednisolone (20 mg once daily for 5 days) or a pla-
cebo for the next episode. The children were stratified
according to amounts of serum eosinophil cationic
protein and eosinophil protein X. As daytime and
nighttime respiratory symptom scores and the need for
hospital admission did not differ between treatment
groups, and no effect of eosinophil priming was seen,
the authors concluded that there is no clear benefit at-
tributable to a short course of parent-initiated prednis-
olone for viral wheeze in children aged 1–5 years.
In conclusion it seems that therapeutic strategy for
treating children with EVW consists of keeping the OCS
at home and having parents commence their use at the
first sign of symptoms is not effectiveness.
Long-acting beta2-agonists and LTRA as adjunct therapy to
ICS
No RCT in this specific age group was published yet
for adjunct therapy to ICS in preschoolers. Only a
small retrospective study using fluticasone propionate
(88–440 μg /day) + salmeterol in 50 preschoolers demon-
strated a significant decrease in wheezing frequency and
healthcare utilization (ED visits and hospitalization) com-
pared to their previous treatment (ICS and/or LTRA) [30].
Therefore, RCTs comparing LABA or LTRA + ICS vs. ICS
alone need to be performed before this combination ther-
apy will be use in infant/preschoolers.
Asthma guidelines (Table 1)
The NAEPP [31], British [32], GINA [33] and Canadian
[34] guidelines recommend that children under 5 years of
age with mild intermittent symptoms (step 1) should be
treated with short-acting beta 2-agonits (SABA) alone.
Those with persistent disease (step 2) should be treated
with controller therapy: all guidelines identify daily low-
dose ICS as the preferred controller, with LRTA suggested
as an alternative therapy [31–34]. But if the asthma is not
controlled with low-dose ICS, the recommendation for
the step 3 varies according to the guidelines (without any
supporting trial): medium-dose ICS [31, 33], or low-dose
ICS + LTRA [32]. As an alternative treatment low-dose
ICS + LTRA was recommended in the GINA guidelines
[33]. Finally, if the preschoolers were not controlled on
step 3, the next step (step 4) was to consider (again with-
out any supporting trial) adding either LABA or LTRA to
a medium-dose ICS [31] or consider referral to a specialist
assessment [32–34]. Only NAEPP guidelines [31] sug-
gested additional steps for children that still with uncon-
trolled asthma: high-dose ICS + either LABA or LTRA for
step 5; and adding OCS for step 6. The other guidelines
[32–34] did not recommend the use of LABA in children
Table 1 Summary of the stepwise approach for managing asthma in children less than 5 years of age according to different
guidelines
NAEPP [31] British [32] GINA [33] Canadian [34]
Step 1 SABA prn SABA prn SABA prn SABA prn
Step 2 Pref: Low-dose ICS Pref: ICS 200–400 μg /daya,b Pref: Daily low-dose ICS Pref: Daily low-dose ICS
Alter: cromolyn or LTRA Alter: LTRA Alter: LTRA or intermittent ICS Alter: LTRA
Step 3 Medium-dose ICS ICS + LTRA Pref: Double low-dose ICS Medium-dose ICS
Alter: Low-dose ICS + LTRA
Step 4 Medium-dose ICS + either
LABA or LTRA
Refer to respiratory pediatrician Pref: Continue controller & refer for
specialist assessment
Referral to asthma specialist
Alter: Add LTRA, increase ICS
frequency, intermittent ICS.
Step 5 High-dose ICS + either
LABA or LTRA
Step 6 High-dose ICS + either
LABA or LTRA
Consider OCS
Alter alternative, GINA Global Initiative for Asthma, ICS inhaled corticosteroids, LABA long active beta-2 agonists, LTRA leukotriene receptor antagonist, NAEPP Na-
tional Asthma Education and Prevention Program, OCS oral corticosteroids, Pref preferred, prn pro re nata, SABA short active beta-2 agonist
abeclometasona dipropionate or equivalent doses
bHigher nominal doses may be required if drug delivery is difficult
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under the age of 5 years. The Canadian guidelines [34]
stated that until more evidence supporting their effective-
ness is available, three commonly used strategies are dis-
couraged: daily LTRA which are less effective than ICS and
should remain a second-line option; stepping-up the daily
dose of ICS during URTI, which remains untested in pre-
schoolers; and the intermittent use of asthma controller
mediations at the onset of symptoms (e.g., LTRA or low or
medium doses of ICS) that has not been convincingly
shown to reduce the number or severity of asthma exacer-
bations. In contrast, use of pre-emptive high-dose of ICS at
the onset of symptoms is effective in reducing the severity
and duration of exacerbation in preschoolers with moderate
or severe viral-induced asthma; however, due to the risk for
overuse and potential side effects, this treatment should be
reserved for asthma specialists and only if daily ICS fails.
Conclusions
Irrespective of the apparent phenotype, daily ICS re-
mains the most effective strategy for preschoolers with
recurrent wheezing, especially those with asthma. For
infants and preschoolers with moderate or severe epi-
sodes of EVW, the use of high intermittent ICS doses
significantly reduce the use of OCS. There is no evi-
dence of effect of intermittent ICS at low-moderate
doses in preschoolers with mild EVW episodes. In pre-
schoolers with asthma, there were no significant differ-
ences between daily vs. intermittent ICS in terms of
asthma exacerbations with insufficient evidence to con-
clude to equivalence; however, for other asthma control
outcomes, daily ICS works significantly better than
intermittent ICS for older children. In preschoolers
with recurrent wheezing or asthma, daily low-dose ICS
seem to be superior to montelukast in reducing symp-
toms and exacerbations and improving lung function.
No RCTs of LABA or LTRA as adjunct to ICS have
been published in preschoolers. Pre-emptive use of
OCS by parents at home at the first sign of symptoms
is not effective in preschoolers with EVW.
In terms of ICS safety, monitor linear growth is es-
sential given that individual susceptibility to these
drugs may vary considerably with attention given to
reducing the dose to the lowest effective dose and
selecting the molecule with least growth suppression.
Ethics approval and consent to participate
Since it is a review paper, the study did not need ethical
committee approval.
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